Should you invest in Trainline?
Ticket seller Trainline offers a useful service – and good prospects for investors


The fund manager Peter Lynch was known for his theory that you should “buy what you know”. Of course, this was a bit more than simply buying the brands you encounter in your day-to-day shopping. Lynch also meant companies that you interact with through your job, or through being part of an industry, and he pointed out that you still had to do your homework to understand the business, balance sheet and valuation. But the logic is clear: sometimes the service you get helps you see why a company makes sense as an investment.
For me, Trainline (LSE: TRN) is a good example of this. The company specialises in selling rail tickets for the entire UK rail network. As someone who does a lot of long train journeys outside London, I find it useful in helping me to find the quickest route and the cheapest ticket, all for a low booking fee. Customer service is also good: in the cases when I’ve accidentally bought more tickets than I need, they have been fine with cancelling them and refunding me, provided I give a reasonable amount of notice.
Is Trainline a good stock to buy?
Of course, Trainline is not universally popular. The RMT trade union recently accused Trainline of ripping off customers and not properly updating timetables to account for delays. However, since the RMT represents those who work in station ticket offices, this should be taken with a pinch of salt. Trainline’s popularity suggests that many users feel that it delivers a far greater degree of convenience compared with ticket machines.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
While there has been talk about the UK government building its own app – especially if the rail network is gradually taken into public ownership over the next five years – the realistic chances of this seem low to me. In any case, Trainline has been diversifying its model, branching out into bus travel (including National Express in the UK), as well as moving into continental Europe (where growing competition between multiple operators creates an opportunity for a single website).
With rail transport being seen as the green alternative to roads, it’s not surprising that Trainline’s revenue has been growing quickly, nearly doubling between 2019 and 2024. It has also managed to expand its operating margins, which are now nearly 20%, and it has a double-digit return on capital employed. Debt is moderate, which should enable it to withstand any downturn. All told, the valuation of 24 times the forecast earnings for 2025 seems reasonable.
Trainline’s shares are also benefiting from short-term momentum. Several brokers have upgraded their earnings forecasts in light of its string of half-year earnings, which caused its shares to jump by more than 20% over the last month. The price is above both the 50-day and 200-day moving average. I would therefore go long at the current price of 404p at £6 per 1p, with a stop-loss of 254p. This would give you a total downside of £900.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Could investing in sugar protect you during a downturn?
Sugar has some defensive qualities during economic downturns, but is now the right time to invest in sugar?
By Dan McEvoy
-
Trump’s tariffs: how should the UK respond?
Every right-thinking person knows that free trade is a surer route to the wealth of nations than protectionism. So, what is Trump thinking?
By Stuart Watkins
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves